About Hanz

Hanz Biotechnology (Suzhou) Co., Ltd. was established in March 2024 in Suzhou Industrial Park.

In August 2024, Hanz was selected for the Suzhou Industrial Park Science and Technology Leading Talent Program.

The company is focused on overcoming critical bottlenecks in RNA drug delivery, including patent barriers, low extrahepatic targeting efficiency, and suboptimal delivery performance.

The Hanz-LNP Delivery Platform is a high-efficiency delivery solution specifically designed for RNA-based therapeutics.

Powered by proprietary technologies, our ionizable lipids are synthesized through a one-step reaction, and our LNPs demonstrate outstanding delivery efficiency, precise extrahepatic targeting capabilities, prolonged expression duration, and excellent biodegradability and safety—ensuring efficient and safe delivery of RNA therapeutics.

Selected Publications

Published on June 26, 2023

Adjuvant Lipids Enhance the Immunogenicity of mRNA Vaccines

Published on Feb 26, 2024

One-pot synthesis of biodegradable lipids significantly reduces production costs.

Published on July 9, 2024

Rapid synthesis of biodegradable lipids enables extrahepatic delivery of mRNA.

Published on Nov 22, 2023

With the A3-directed chemical optimization strategy, the R&D cycle for ionizable lipids has been shortened from several years to just a few weeks.